Re-treatment of Participants With Paget's Disease Using Zoledronic Acid

Inclusion Criteria: * Written Informed Consent * Participants with Paget's disease randomized to the zoledronic acid arm from the CZOL446K2304 and CZOL446K2305 core studies and who were responders by 6 months * Confirmed relapse of Paget's disease of bone (i.e., serum alkaline phosphatase (SAP) above upper limit of normal (ULN), bone scan, worsening clinical symptoms) Exclusion Criteria: * A participant previously treated with zoledronic acid who relapsed and was retreated with anti-resorptive bisphosphonate or calcitonin therapy within the last 12 months * Bisphosphonate Hypersensitivity * Participants with suspected/proven metastases at re-treatment * Calculated creatinine clearance \<35 milliliter/minute (mL/min) at screening * Serum calcium level \<2.07 millimole/liter (mmol/L) at screening * Active primary hyperparathyroidism, hyperparathyroidism, hypoparathyroidism or hypothyroidism Other protocol-defined inclusion/exclusion criteria may apply.